| Autor: |
Kim, Hichul, El-Khoury, Victoria, Schulte, Nadine, Zhan, Tianzuo, Betge, Johannes, Cousin, Loic, Felli, Emanuele, Pessaux, Patrick, Ogier, Arnaud, Opitz, Oliver G, Ku, Bosung, Ebert, Matthias P, Kwon, Yong-Jun |
| Zdroj: |
Cancer Biology and Therapy; December 2022, Vol. 23 Issue: 1 p96-102, 7p |
| Abstrakt: |
ABSTRACTLung carcinoids are neuroendocrine tumors representing 1 to 2% of lung cancers. This study outlines the case of a patient with a metastatic lung atypical carcinoid who presented with a pleural effusion and progression of liver metastases after developing resistance to conventional treatments. Personalized functional profiling (PFP), i.e. drug screening, was performed in ex-vivospheroids obtained from the patient’s liver metastasis to identify potential therapeutic options. The drug screening results revealed cediranib, an antiangiogenic drug, as a hit drug for this patient, from a library of 66 Food and Drug Administration (FDA)-approved and investigational drugs. Based on the PFP results and the reported evidence of clinical efficacy of bevacizumab and capecitabine combination in gastro-intestinal neuroendocrine tumors, this combination was given to the patient. Four months later, the pleural effusion and pleura carcinosis regressed and the liver metastasis did not progress. The patient experienced 2 years of a stable disease under the PFP-guided personalized treatment. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
